These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 17610079)
1. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Hadighi R; Boucher P; Khamesipour A; Meamar AR; Roy G; Ouellette M; Mohebali M Parasitol Res; 2007 Oct; 101(5):1319-22. PubMed ID: 17610079 [TBL] [Abstract][Full Text] [Related]
2. Comparison of Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583 [TBL] [Abstract][Full Text] [Related]
3. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. Hadighi R; Mohebali M; Boucher P; Hajjaran H; Khamesipour A; Ouellette M PLoS Med; 2006 May; 3(5):e162. PubMed ID: 16605301 [TBL] [Abstract][Full Text] [Related]
4. In Vitro Sensitivity of Cutaneous Ginouvès M; Simon S; Nacher M; Demar M; Carme B; Couppié P; Prévot G Am J Trop Med Hyg; 2017 May; 96(5):1143-1150. PubMed ID: 28167598 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of In vitro and In vivo Drug Efficacy Over Leishmania tropica: A Pilot Study. Özbilgin A; Çavuş İ; Yıldırım A; Kaya T; Ertabaklar H Turkiye Parazitol Derg; 2018 Mar; 42(1):11-19. PubMed ID: 29780014 [TBL] [Abstract][Full Text] [Related]
6. In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs. Jamal Q; Khan NH; Wahid S; Awan MM; Sutherland C; Shah A Exp Parasitol; 2015 Jul; 154():93-7. PubMed ID: 25911243 [TBL] [Abstract][Full Text] [Related]
7. Expression analysis of activated protein kinase C gene (LACK1) in antimony sensitive and resistant Leishmania tropica clinical isolates using real-time RT-PCR. Hajjaran H; Kazemi-Rad E; Mohebali M; Oshaghi MA; Khadem-Erfan MB; Hajaliloo E; Reisi Nafchi H; Raoofian R Int J Dermatol; 2016 Sep; 55(9):1020-6. PubMed ID: 27336481 [TBL] [Abstract][Full Text] [Related]
8. Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model. Utaile M; Kassahun A; Abebe T; Hailu A Exp Parasitol; 2013 May; 134(1):68-75. PubMed ID: 23434530 [TBL] [Abstract][Full Text] [Related]
9. Comparative proteomics study on meglumine antimoniate sensitive and resistant Leishmania tropica isolated from Iranian anthroponotic cutaneous leishmaniasis patients. Hajjaran H; Azarian B; Mohebali M; Hadighi R; Assareh A; Vaziri B East Mediterr Health J; 2012 Feb; 18(2):165-71. PubMed ID: 22571094 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of meglumine antimoniate against L. tropica in a recently emerged focus of cutaneous leishmaniasis in Birjand, eastern Islamic Republic of Iran. Karamian M; Bojd MS; Salehabadi A; Hemmati M; Barati DA East Mediterr Health J; 2015 Jun; 21(4):280-6. PubMed ID: 26077523 [TBL] [Abstract][Full Text] [Related]
12. Involvement of tryparedoxin peroxidase (TryP) and trypanothione reductase (TryR) in antimony unresponsive of Leishmania tropica clinical isolates of Iran. Nateghi-Rostami M; Tasbihi M; Darzi F Acta Trop; 2022 Jun; 230():106392. PubMed ID: 35276060 [TBL] [Abstract][Full Text] [Related]
13. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran. Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238 [TBL] [Abstract][Full Text] [Related]
14. Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Grogl M; Thomason TN; Franke ED Am J Trop Med Hyg; 1992 Jul; 47(1):117-26. PubMed ID: 1322070 [TBL] [Abstract][Full Text] [Related]
15. Identification of antimony resistance markers in Leishmania tropica field isolates through a cDNA-AFLP approach. Kazemi-Rad E; Mohebali M; Khadem-Erfan MB; Saffari M; Raoofian R; Hajjaran H; Hadighi R; Khamesipour A; Rezaie S; Abedkhojasteh H; Heidari M Exp Parasitol; 2013 Oct; 135(2):344-9. PubMed ID: 23928349 [TBL] [Abstract][Full Text] [Related]
16. Sensitivity to Glucantime of Leishmania viannia isolated from patients prior to treatment. Robledo SM; Valencia AZ; Saravia NG J Parasitol; 1999 Apr; 85(2):360-6. PubMed ID: 10219320 [TBL] [Abstract][Full Text] [Related]
17. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Ephros M; Bitnun A; Shaked P; Waldman E; Zilberstein D Antimicrob Agents Chemother; 1999 Feb; 43(2):278-82. PubMed ID: 9925518 [TBL] [Abstract][Full Text] [Related]
18. Glucantime resistant Leishmania promastigotes are sensitive to pentostam. Moreira ES; Guerra JB; Petrillo-Peixoto Mde L Rev Soc Bras Med Trop; 1992; 25(4):247-50. PubMed ID: 1340539 [TBL] [Abstract][Full Text] [Related]
19. Involvement of thiol metabolism in resistance to glucantime in Leishmania tropica. Arana FE; Pérez-Victoria JM; Repetto Y; Morello A; Castanys S; Gamarro F Biochem Pharmacol; 1998 Nov; 56(9):1201-8. PubMed ID: 9802332 [TBL] [Abstract][Full Text] [Related]
20. Current scenario of drug development for leishmaniasis. Croft SL; Seifert K; Yardley V Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]